Literature DB >> 15328100

Impact of alpha interferon and ribavirin on the function of maturing dendritic cells.

Eleanor Barnes1, Mariolina Salio, Vincenzo Cerundolo, Joanne Medlin, Shona Murphy, Geoffrey Dusheiko, Paul Klenerman.   

Abstract

Alpha interferon and ribavirin are required in combination to achieve a sustained virological response in the treatment of hepatitis C virus (HCV) infection. Alpha interferon has direct antiviral activity and also enhances HCV-specific T-cell responses. Ribavirin has little direct activity against HCV but reduces hepatic inflammation. It is therefore likely that these drugs in combination have hitherto unidentified immunological effects. In the present study we investigated the effects of alpha interferon and ribavirin on dendritic cell (DC) maturation and cytokine production induced by double-stranded RNA in vitro. Alpha interferon alone enhanced the expression of HLA class I, HLA class II, and CD86 on immature DCs but did not stimulate full DC maturation, which requires the expression of CD83. Alpha interferon enhanced the production of interleukin 12 p70 [IL-12(p70)] and tumor necrosis factor alpha (TNF-alpha) but had no effect on IL-10 production. In contrast, ribavirin at physiological doses had no effect on DC maturation but markedly suppressed the production of TNF-alpha, IL-10, and IL-12(p70). The suppression of cytokines by ribavirin cannot be explained by the induction of DC apoptosis or cell death. Quantitative PCR confirmed that cytokine suppression occurs at the level of mRNA. The suppression of IL-12(p70) and TNF-alpha in maturing DCs may explain the reduction in hepatic inflammation observed during ribavirin monotherapy. Combination alpha interferon-ribavirin therapy may alter the cytokine profile of maturing DCs overall by suppressing IL-10 production but maintaining IL-12(p70) and TNF-alpha production, a pattern that would favor viral elimination through downstream effects on T cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15328100      PMCID: PMC514729          DOI: 10.1128/AAC.48.9.3382-3389.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  36 in total

1.  Inhibition of influenza virus ribonucleic acid polymerase by ribavirin triphosphate.

Authors:  B Eriksson; E Helgstrand; N G Johansson; A Larsson; A Misiorny; J O Norén; L Philipson; K Stenberg; G Stening; S Stridh; B Oberg
Journal:  Antimicrob Agents Chemother       Date:  1977-06       Impact factor: 5.191

2.  Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C.

Authors:  M E Cramp; S Rossol; S Chokshi; P Carucci; R Williams; N V Naoumov
Journal:  Gastroenterology       Date:  2000-02       Impact factor: 22.682

3.  Inhibition of dendritic cell maturation by herpes simplex virus.

Authors:  M Salio; M Cella; M Suter; A Lanzavecchia
Journal:  Eur J Immunol       Date:  1999-10       Impact factor: 5.532

4.  Ribavirin inhibits DNA, RNA, and protein synthesis in PHA-stimulated human peripheral blood mononuclear cells: possible explanation for therapeutic efficacy in patients with chronic HCV infection.

Authors:  Volker Meier; Erik Bürger; Sabine Mihm; Bernhard Saile; Giuliano Ramadori
Journal:  J Med Virol       Date:  2003-01       Impact factor: 2.327

5.  Mechanism of action of 1- -D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent.

Authors:  D G Streeter; J T Witkowski; G P Khare; R W Sidwell; R J Bauer; R K Robins; L N Simon
Journal:  Proc Natl Acad Sci U S A       Date:  1973-04       Impact factor: 11.205

6.  The C-terminal domain of pol II and a DRB-sensitive kinase are required for 3' processing of U2 snRNA.

Authors:  Joanne E Medlin; Patricia Uguen; Alice Taylor; David L Bentley; Shona Murphy
Journal:  EMBO J       Date:  2003-02-17       Impact factor: 11.598

7.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

Authors:  Michael W Fried; Mitchell L Shiffman; K Rajender Reddy; Coleman Smith; George Marinos; Fernando L Gonçales; Dieter Häussinger; Moises Diago; Giampiero Carosi; Daniel Dhumeaux; Antonio Craxi; Amy Lin; Joseph Hoffman; Jian Yu
Journal:  N Engl J Med       Date:  2002-09-26       Impact factor: 91.245

8.  Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin.

Authors:  Jay H Hoofnagle; Marc G Ghany; David E Kleiner; Edward Doo; Theo Heller; Kittichai Promrat; Janus Ong; Farooq Khokhar; Alejandro Soza; David Herion; Yoon Park; James E Everhart; T Jake Liang
Journal:  Hepatology       Date:  2003-07       Impact factor: 17.425

9.  The dynamics of T-lymphocyte responses during combination therapy for chronic hepatitis C virus infection.

Authors:  Eleanor Barnes; Gillian Harcourt; Dave Brown; Michaela Lucas; Rodney Phillips; Geoffrey Dusheiko; Paul Klenerman
Journal:  Hepatology       Date:  2002-09       Impact factor: 17.425

10.  Analysis of successful immune responses in persons infected with hepatitis C virus.

Authors:  F Lechner; D K Wong; P R Dunbar; R Chapman; R T Chung; P Dohrenwend; G Robbins; R Phillips; P Klenerman; B D Walker
Journal:  J Exp Med       Date:  2000-05-01       Impact factor: 14.307

View more
  19 in total

1.  Interleukin-12: an update on its immunological activities, signaling and regulation of gene expression.

Authors:  Jianguo Liu; Shanjin Cao; Sunjung Kim; Elaine Y Chung; Yoichiro Homma; Xiuqin Guan; Violeta Jimenez; Xiaojing Ma
Journal:  Curr Immunol Rev       Date:  2005-06

2.  Do DCs influence the antiviral effect of interferon/ribavirin by changing their profile during the therapy?

Authors:  Hiroki Takahashi; Mikio Zeniya
Journal:  J Gastroenterol       Date:  2006-08       Impact factor: 7.527

3.  The emergence of obsessive compulsive and compulsive buying symptomatology after acute stress and short-term use of ribavirin: case reports.

Authors:  Görkem Karakaş Uğurlu; Mustafa Uğurlu; Ali Cayköylü
Journal:  Ther Adv Psychopharmacol       Date:  2013-08

4.  Inhibitory effect of a nucleotide analog on infectious salmon anemia virus infection.

Authors:  Andrea Rivas-Aravena; Eva Vallejos-Vidal; Marcelo Cortez-San Martin; Felipe Reyes-Lopez; Mario Tello; Patricia Mora; Ana María Sandino; Eugenio Spencer
Journal:  J Virol       Date:  2011-06-08       Impact factor: 5.103

5.  Monocyte activation by interferon α is associated with failure to achieve a sustained virologic response after treatment for hepatitis C virus infection.

Authors:  Dennis J Hartigan-O'Connor; Din Lin; James C Ryan; Valentina A Shvachko; Myrna L Cozen; Mark R Segal; Norah A Terrault; Lewis L Lanier; M Michele Manos; Joseph M McCune
Journal:  J Infect Dis       Date:  2013-12-10       Impact factor: 5.226

6.  Hepatitis C virus modulates human monocyte-derived dendritic cells.

Authors:  E A Eksioglu; J R Bess; H Zhu; Y Xu; H-J Dong; J Elyar; D R Nelson; C Liu
Journal:  J Viral Hepat       Date:  2010-11       Impact factor: 3.728

7.  Role of A20 in interferon-α-mediated functional restoration of myeloid dendritic cells in patients with chronic hepatitis C.

Authors:  Li Ma; Yun Zhou; Ying Zhang; Yuan Li; Yonghong Guo; Yu He; Jiuping Wang; Jianqi Lian; Chunqiu Hao; Jonathan P Moorman; Zhi Q Yao; Yongxing Zhou; Zhansheng Jia
Journal:  Immunology       Date:  2014-12       Impact factor: 7.397

8.  Hepatitis C and innate immunity: recent advances.

Authors:  Gyongyi Szabo; Angela Dolganiuc
Journal:  Clin Liver Dis       Date:  2008-08       Impact factor: 6.126

9.  Hepatitis C virus lymphotropism and peculiar immunological phenotype: effects on natural history and antiviral therapy.

Authors:  Paolo Conca; Giovanni Tarantino
Journal:  World J Gastroenterol       Date:  2009-05-21       Impact factor: 5.742

Review 10.  Innate immune cell networking in hepatitis C virus infection.

Authors:  Banishree Saha; Gyongyi Szabo
Journal:  J Leukoc Biol       Date:  2014-07-07       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.